Consequences of inhibition of bumetanide metabolism in rodents on brain penetration and effects of bumetanide in chronic models of epilepsy

European Journal of Neuroscience

Volumn 39, Issue 4, 2014, Pages 673-687

  Töpfer, Manuel ^a,b   Töllner, Kathrin ^a,b   Brandt, Claudia ^a,b   Twele, Friederike ^a,b   Bröer, Sonja ^a,b   Löscher, Wolfgang ^a,b  

^a UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

^b CENTER FOR SYSTEMS NEUROSCIENCE   (Germany)

Author keywords

Blood brain barrier; Diuresis; Epilepsy; Kindling; Piperonyl butoxide; Seizures

Indexed keywords

BLOOD-BRAIN BARRIER; DIURESIS; EPILEPSY; KINDLING; PIPERONYL BUTOXIDE; SEIZURES;

ANIMALS; ANTIOXIDANTS; BRAIN; BUMETANIDE; DIURETICS; KAINIC ACID; MICE; PIPERONYL BUTOXIDE; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS; STATUS EPILEPTICUS;

EID: 84894105348     PISSN: 0953816X     EISSN: 14609568     Source Type: Journal    
DOI: 10.1111/ejn.12424     Document Type: Article

References (65)

1. Abbott, N.J. (2005) Dynamics of CNS barriers: evolution, differentiation, and modulation. Cell. Mol. Neurobiol., 25, 5-23.
2. Alvarez-Leefmans, F.J. (2012) Intracellular chloride regulation. In Sperelakis, N. (Ed.), Cell Physiology Sourcebook Essentials of Membrane Biophysics, 4th edn. Academic Press, London, pp. 221-259.
3. Ater, S.B., Swinyard, E.A., Tolman, K.G. & Franklin, M.R. (1984) Anticonvulsant activity and neurotoxicity of piperonyl butoxide in mice. Epilepsia, 25, 551-555.
4. Baltes, S., Fedrowitz, M., Luna-Tortós, C., Potschka, H. & Löscher, W. (2007) Valproic acid is not a substrate for P-glycoprotein or multidrug resistance proteins 1 and 2 in a number of in vitro and in vivo transport assays. J. Pharmacol. Exp. Ther., 320, 331-343.
5. A receptor reversal potential due to altered chloride homeostasis is widespread after status epilepticus. Epilepsia, 52, 1570-1578.
6. Ben-Ari, Y. (2012) Blocking seizures with the diuretic bumetanide: promises and pitfalls. Epilepsia, 53, 394-396.
7. Bertram, E. (2007) The relevance of kindling for human epilepsy. Epilepsia, 48(Suppl 2), 65-74.
8. Blaesse, P., Airaksinen, M.S., Rivera, C. & Kaila, K. (2009) Cation-chloride cotransporters and neuronal function. Neuron, 61, 820-838.
9. Bragin, D.E., Sanderson, J.L., Peterson, S., Connor, J.A. & Muller, W.S. (2009) Development of epileptiform excitability in the deep entorhinal cortex after status epilepticus. Eur. J. Neurosci., 30, 611-624.
10. Brandt, C., Nozadze, M., Heuchert, N., Rattka, M. & Löscher, W. (2010) Disease-modifying effects of phenobarbital and the NKCC1 inhibitor bumetanide in the pilocarpine model of temporal lobe epilepsy. J. Neurosci., 30, 8602-8612.
11. Cleary, R.T., Sun, H., Huynh, T., Manning, S.M., Li, Y., Rotenberg, A., Talos, D.M., Kahle, K.T., Jackson, M., Rakhade, S.N., Berry, G. & Jensen, F.E. (2013) Bumetanide enhances phenobarbital efficacy in a rat model of hypoxic neonatal seizures. PLoS One, 8, e57148.
12. Cohen, M.R., Hinsch, E., Vergona, R., Ryan, J., Kolis, S.J. & Schwartz, M.A. (1976) A comparative diuretic and tissue distribution study of bumetanide and furosemide in the dog. J. Pharmacol. Exp. Ther., 197, 697-702.
13. Dzhala, V.I., Talos, D.M., Sdrulla, D.A., Brumback, A.C., Mathews, G.C., Benke, T.A., Delpire, E., Jensen, F.E. & Staley, K.J. (2005) NKCC1 transporter facilitates seizures in the developing brain. Nat. Med., 11, 1205-1213.
14. Dzhala, V.I., Brumback, A.C. & Staley, K.J. (2008) Bumetanide enhances phenobarbital efficacy in a neonatal seizure model. Ann. Neurol., 63, 222-235.
15. El Bahh, B., Balosso, S., Hamilton, T., Herzog, H., Beck-Sickinger, A.G., Sperk, G., Gehlert, D.R., Vezzani, A. & Colmers, W.F. (2005) The anti-epileptic actions of neuropeptide Y in the hippocampus are mediated by Y and not Y receptors. Eur. J. Neurosci., 22, 1417-1430.
16. Frey, H.H. (1975) Pharmacology of bumetanide. Postgrad. Med. J., 51(Suppl 6), 14-18.
17. Gernert, M. & Löscher, W. (2001) Lack of robust anticonvulsant effects of muscimol microinfusions in the anterior substantia nigra of kindled rats. Eur. J. Pharmacol., 432, 35-41.
18. Goda, S., Thorsheim, H.R., Taskar, K.S., Thomas, A.J. & Smith, Q.R. (2010) Restricted Brain Distribution of Bumetanide is Mediated by Active Efflux Transporters (Rat Oatp & OAT3) at the Blood-Brain Barrier. American Association of Pharmaceutical Scientists Annual Meeting Abstracts, Nov. 14-18, 2010, New Orleans, LA.
19. Gröticke, I., Hoffmann, K. & Löscher, W. (2008) Behavioral alterations in a mouse model of temporal lobe epilepsy induced by intrahippocampal injection of kainate. Exp. Neurol., 213, 71-83.
20. Haas, M. & Forbush, B. III (1998) The Na-K-Cl cotransporters. J. Bioenerg. Biomembr., 30, 161-172.
21. Haley, T.J. (1978) Piperonyl butoxide, α[2-(2-butoxyethoxy)ethoxy]-4, 5-methylenedioxy-2-propyltoluene: a review of the literature. Ecotox. Environ. Safe., 2, 9-31.
22. Halladay, S.C., Sipes, I.G. & Carter, D.E. (1977) Diuretic effect and metabolism of bumetanide in man. Clin. Pharmacol. Ther., 22, 179-187.
23. Halladay, S.C., Carter, D.E. & Sipes, I.G. (1978) A relationship between the metabolism of bumetanide and its diuretic activity in the rat. Drug Metab. Dispos., 6, 45-49.
24. Hasannejad, H., Takeda, M., Taki, K., Shin, H.J., Babu, E., Jutabha, P., Khamdang, S., Aleboyeh, M., Onozato, M.L., Tojo, A., Enomoto, A., Anzai, N., Narikawa, S., Huang, X.L., Niwa, T. & Endou, H. (2004) Interactions of human organic anion transporters with diuretics. J. Pharmacol. Exp. Ther., 308, 1021-1029.
25. Helmy, M.M., Tolner, E.A., Vanhatalo, S., Voipio, J. & Kaila, K. (2011) Brain alkalosis causes birth asphyxia seizures, suggesting therapeutic strategy. Ann. Neurol., 69, 493-500.
26. Inoue, M., Uriu, T., Otani, H., Hara, M., Omori, K. & Inagaki, C. (1989) Intracerebroventricular injection of ethacrynic acid induces status epilepticus. Eur. J. Pharmacol., 166, 101-106.
27. Javaheri, S., Davis, C. & Rogers, D.H. (1993) Ionic composition of cisternal CSF in acute respiratory acidosis: lack of effect of large dose bumetanide. J. Neurochem., 61, 1525-1529.
28. Kahle, K.T. & Staley, K.J. (2008) The bumetanide-sensitive Na-K-2Cl cotransporter NKCC1 as a potential target of a novel mechanism-based treatment strategy for neonatal seizures. Neurosurg. Focus, 25, 1-8.
29. Kahle, K.T., Staley, K.J., Nahed, B.V., Gamba, G., Hebert, S.C., Lifton, R.P. & Mount, D.B. (2008) Roles of the cation-chloride cotransporters in neurological disease. Nat. Clin. Pract. Neuro., 4, 490-503.
30. Kim, E.J. & Lee, M.G. (2001) Pharmacokinetics and pharmacodynamics of intravenous bumetanide in mutant Nagase analbuminemic rats: importance of globulin binding for the pharmacodynamic effects. Biopharm. Drug Dispos., 22, 147-156.
31. Kobayashi, Y., Ohbayashi, M., Kohyama, N. & Yamamoto, T. (2005) Mouse organic anion transporter 2 and 3 (mOAT2/3[Slc22a7/8]) mediates the renal transport of bumetanide. Eur. J. Pharmacol., 524, 44-48.
32. Kolis, S.J., Williams, T.H. & Schwartz, M.A. (1976) Identification of the urinary metabolites of 14C-bumetanide in the rat and their excretion by rats and dogs. Drug Metab. Dispos., 4, 169-176.
33. Langer, M., Brandt, C. & Löscher, W. (2011) Marked strain and substrain differences in induction of status epilepticus and subsequent development of neurodegeneration, epilepsy, and behavioral alterations in rats. Epilepsy Res., 96, 207-224.
34. - co-transporter 2 (KCC2) in CA1 region of hippocampus following lithium-pilocarpine induced status epilepticus (PISE). Brain Res., 1221, 141-146.
35. Li, Y., Cleary, R., Kellogg, M., Soul, J.S., Berry, G.T. & Jensen, F.E. (2011) Sensitive isotope dilution liquid chromatography/tandem mass spectrometry method for quantitative analysis of bumetanide in serum and brain tissue. J Chromatogr. B Analyt. Technol. Biomed. Life Sci., 879, 998-1002.
36. Löscher, W. (1998) Pharmacology of glutamate receptor antagonists in the kindling model. In Corcoran, M.E. & Moshé, S.L. (Eds), Kindling 5. Plenum Press, New York, pp. 435-449.
37. Löscher, W. (2002) Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs, 16, 669-694.
38. Löscher, W. & Brandt, C. (2010) Prevention or modification of epileptogenesis after brain insults: experimental approaches and translational research. Pharmacol. Rev., 62, 668-700.
39. Löscher, W., Puskarjov, M. & Kaila, K. (2013) Cation-chloride cotransporters NKCC1 and KCC2 as potential targets for novel antiepileptic and antiepileptogenic treatments. Neuropharmacology, 69, 62-74.
40. Magnussen, M.P. & Eilertsen, E. (1974) Species differences in the diuretic activity and metabolism of bumetanide. N.-S. Arch. Pharmacol., 282(Suppl.), R61.
41. Maroso, M., Balosso, S., Ravizza, T., Iori, V., Wright, C.I., French, J. & Vezzani, A. (2011) Interleukin-1β biosynthesis inhibition reduces acute seizures and drug resistant chronic epileptic activity in mice. Neurotherapeutics, 8, 304-315.
42. Mazarati, A., Shin, D. & Sankar, R. (2009) Bumetanide inhibits rapid kindling in neonatal rats. Epilepsia, 50, 2117-2122.
43. Miles, R., Blaesse, P., Huberfeld, G., Wittner, L. & Kaila, K. (2012) Chloride homeostasis and GABA signaling in temporal lobe epilepsy. In Noebels, J.L., Avoli, M., Rogawski, M.A., Olsen, R.W. & Delgado-Escueta, A.V. (Eds), Jasper's Basic Mechanisms of the Epilepsies, 4th edn. Oxford University Press, New York, pp. 581-590.
44. Morimoto, K., Fahnestock, M. & Racine, R.J. (2004) Kindling and status epilepticus models of epilepsy: rewiring the brain. Prog. Neurobiol., 73, 1-60.
45. Morris, M.E. & Felmlee, M.A. (2008) Overview of the proton-coupled MCT (SLC16A) family of transporters: characterization, function and role in the transport of the drug of abuse gamma-hydroxybutyric acid. AAPS J., 10, 311-321.
46. Murakami, Y., Kohyama, N., Kobayashi, Y., Ohbayashi, M., Ohtani, H., Sawada, Y. & Yamamoto, T. (2005) Functional characterization of human monocarboxylate transporter 6 (SLC16A5). Drug Metab. Dispos., 33, 1845-1851.
47. - cotransporter, in the rat piriform cortex. Neurosci. Res., 44, 225-229.
48. Okabe, A., Yokokura, M., Toyoda, H., Shimizu-Okabe, C., Ohno, K., Sato, K. & Fukuda, A. (2003) Changes in chloride homeostasis-regulating gene expressions in the rat hippocampus following amygdala kindling. Brain Res., 990, 221-226.
49. Olsen, U.B. (1977) The pharmacology of bumetanide. Acta Pharmacol. Tox. (Copenh.), 41, 1-29.
50. Ostergaard, E.H., Magnussen, M.P., Nielsen, C.K., Eilertsen, E. & Frey, H.H. (1972) Pharmacological properties of 3-n-butylamino-4-phenoxy-5-sulfamylbenzoic acid (bumetanide), a new potent diuretic. Arznei.-Forschung, 22, 66-72.
51. Pathak, H.R., Weissinger, F., Terunuma, M., Carlson, G.C., Hsu, F.C., Moss, S.J. & Coulter, D.A. (2007) Disrupted dentate granule cell chloride regulation enhances synaptic excitability during development of temporal lobe epilepsy. J. Neurosci., 27, 14012-14022.
52. Paxinos, G. & Franklin, K.B.J. (2001) The Mouse Brain in Stereotaxic Coordinates. Academic Press, New York.
53. Paxinos, G. & Watson, C. (2007) The Rat Brain in Stereotaxic Coordinates, 6th edn. Elsevier, Amsterdam.
54. Payne, J.A., Rivera, C., Voipio, J. & Kaila, K. (2003) Cation-chloride co-transporters in neuronal communication, development and trauma. Trends Neurosci., 26, 199-206.
55. Racine, R.J. (1972) Modification of seizure activity by electrical stimulation: II. Motor seizure. Electroen. Clin. Neuro., 32, 281-294.
56. Riban, V., Bouilleret, V., Pham, L., Fritschy, J.M., Marescaux, C. & Depaulis, A. (2002) Evolution of hippocampal epileptic activity during the development of hippocampal sclerosis in a mouse model of temporal lobe epilepsy. Neuroscience, 112, 101-111.
57. Rivera, C., Li, H., Thomas-Crusells, J., Lahtinen, H., Viitanen, T., Nanobashvili, A., Kokaia, Z., Airaksinen, M.S., Voipio, J., Kaila, K. & Saarma, M. (2002) BDNF-induced TrkB activation down-regulates the K + -Cl- cotransporter KCC2 and impairs neuronal Cl- extrusion. J. Cell Biol., 159, 747-752.
58. Schuchmann, S., Schmitz, D., Rivera, C., Vanhatalo, S., Salmen, B., Mackie, K., Sipila, S.T., Voipio, J. & Kaila, K. (2006) Experimental febrile seizures are precipitated by a hyperthermia-induced respiratory alkalosis. Nat. Med., 12, 817-823.
59. Schwartz, M.A. (1981) Metabolism of bumetanide. J. Clin. Pharmacol., 21, 555-563.
60. Shen, D.D. (1999) Valproate: absorption, distribution, and excretion. In Löscher, W. (Ed.), Valproate. Birkhäuser, Basle, pp. 77-90.
61. Töllner, K., Wolf, S., Löscher, W. & Gernert, M. (2011) The anticonvulsant response to valproate in kindled rats is correlated with its effect on neuronal firing in the substantia nigra pars reticulata: a new mechanism of pharmacoresistance. J. Neurosci., 31, 16423-16434.
62. Toutain, P.L. & Bousquet-Mélou, A. (2004) Bioavailability and its assessment. J. Vet. Pharmacol. Ther., 27, 455-466.
63. Tsuji, A. (2005) Small molecular drug transfer across the blood-brain barrier via carrier-mediated transport systems. NeuroRx, 2, 54-62.
64. Vijay, N. & Morris, M.E. (2013) Role of monocarboxylate transporters in drug delivery to the brain. Curr. Pharm. Design, PMID: 23789956. [Epub ahead of print].
65. Ward, A. & Heel, R.C. (1984) Bumetanide. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use. Drugs, 28, 426-464.